Alogliptin+Pioglitazone Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 12.5 mg / 30 mg, 25 mg / 15 mg, 25 mg / 30 mg, 25 mg / 45 mg
Reference Brands: Oseni (USA), Incresync(EU)
Category:
Diabetes
Alogliptin/pioglitazone is an oral medication for type 2 diabetes mellitus. It combines alogliptin, a DPP-4 inhibitor, and pioglitazone, a thiazolidinedione, to help control blood sugar levels. The combination improves insulin response and reduces liver glucose production. Taken once daily, it is used when diet, exercise, or single-drug therapy is insufficient.
Alogliptin+pioglitazone is available in Tablets
and strengths such as 12.5 mg / 30 mg, 25 mg / 15 mg, 25 mg / 30 mg, 25 mg / 45 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Alogliptin+pioglitazone is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Alogliptin+pioglitazone can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing